1. To investigate the role of interleukin-1β in chronic ulcerative colitis, we quantified interleukin-1β steady-state release into the colonic lumen.
2. We studied 26 patients with untreated chronic ulcerative colitis and seven patients with irritable bowel syndrome who served as disease controls. In seven ulcerative colitis patients, the disease was inactive and in 19 it was mild to moderately active, according to clinical and colonoscopic criteria. Seven patients with active colitis were studied before and after 4 weeks of treatment with oral 5-aminosalicylic acid.
3. Colonic perfusions were performed using a double-lumen technique. An isotonic solution was continuously infused 50 cm from the anal verge at 5 ml/min, and was recovered 30 cm distally by siphonage. Interleukin-1β was measured by ELISA, polymorphonuclear elastase by immunoactivation and leukotriene B4 by specific RIA.
4. All control patients and five out of seven patients with inactive colitis had undetectable interleukin-1β release. In active colitis, the release of interleukin-1β was detected in 17 out of 19 patients (median 500 pg/min, interquartiles 270–1582 pg/min, P < 0.01 compared with control subjects and patients with inactive colitis). Elastase and leukotriene B4 release were also significantly increased in active colitis compared with inactive colitis and controls. Leukotriene B4 release was similar in inactive colitis and controls, whereas elastase release was higher in inactive colitis than in controls. Five out of seven patients with colitis improved after treatment with 5-aminosalicylic acid. In all responder patients, interleukin-1β became undetectable or declined.
5. Our results demonstrate under conditions in vivo that active colitis is associated with enhanced interleukin-1β release into the colonic lumen whereas such release does not occur in remission, supporting the concept that ulcerative colitis flare-ups involve increased interleukin-1β production.
